|
||
|
ZelleRx Corporation
Download PDF Members: ZelleRx is committed to being the industry leader in the development of natural killer cell therapies through products derived from its proprietary NK-92 cell line. These natural killer cells have been shown to seek and destroy cancer tumor cells within the human body. In recent years, the use of NK cells for cancer therapy has emerged as a leading novel approach. NK cells were originally identified at the National Cancer Institute in the laboratories of Ronald Herberman, M.D., a member of the ZelleRx Board of Directors. The first product being developed by ZelleRx is ZRx101, based on the unmodified NK-92 cell line. ZRx101 has been demonstrated in numerous preclinical studies to be effective at killing a broad scope of cancers. ZelleRx is currently finishing Phase I clinical trials for ZRx101.
This page has been viewed 776 times since April 2007, the link to the organisation's website has been followed 247 times Recent Search Terms used to find this page: zellerx | t | ZelleRx | ZRx101 zellerx | zellerx | zellerx | zellerx | zelleRx | zelleRx | zellerx | . Search for more companies in Chicago Search for more companies in Illinois This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified. BioPortfolio search results for ZelleRx Corporation | ||||||||||||||||||||||||||
Nothing in this website should be used in place of personal medical
advice from your own qualified medical practitioner. See
User
Agreement |
All rights reserved. All other trademarks recognized. |
|
|